These results provide the framework for clinical application of heteroclitic BCMA<sub>72-80</sub> peptide, alone and in combination with anti-LAG3 and/or anti-OX40 therapy, in vaccination and/or adoptive immunotherapeutic strategies to generate long-lasting anti-tumor immunity in patients with MM or other BCMA expressing tumors.
Taken together, these data suggest that LAG3-expressing CD4<sup>+</sup>CD25<sup>-</sup> T cells represent another regulatory immune cell type with potential to interfere with anti-tumor immunity.